Connection

Robert Harrington to United States

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about United States.
Robert Harrington
Connection Strength
1.179
United States
  1. Protecting Medical Trainees on the COVID-19 Frontlines Saves Us All. Circulation. 2020 May 05; 141(18):e775-e777.
    View in: PubMed
    Score: 0.072
  2. Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. Circulation. 2020 03 10; 141(10):e615-e644.
    View in: PubMed
    Score: 0.071
  3. Translating Science Into Policy: An Important Collaboration Among Researchers, Clinicians, and Advocacy at the American Heart Association. Circulation. 2019 09 09; 140(10):e545-e546.
    View in: PubMed
    Score: 0.069
  4. Assessing research results in the medical literature: trust but verify. JAMA Intern Med. 2013 Jun 24; 173(12):1053-5.
    View in: PubMed
    Score: 0.045
  5. Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being. JAMA. 2012 Nov 07; 308(17):1743-4.
    View in: PubMed
    Score: 0.043
  6. Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J. 2010 Nov; 160(5):795-803.e2.
    View in: PubMed
    Score: 0.037
  7. There is a role for industry-sponsored education in cardiology. Circulation. 2010 May 25; 121(20):2221-7.
    View in: PubMed
    Score: 0.036
  8. Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration. Circulation. 2008 Jun 03; 117(22):2956-7.
    View in: PubMed
    Score: 0.032
  9. Conflict of interest. Am Heart J. 2004 Feb; 147(2):228-37.
    View in: PubMed
    Score: 0.023
  10. 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. Circulation. 2021 06 22; 143(25):e1035-e1087.
    View in: PubMed
    Score: 0.019
  11. 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. J Am Coll Cardiol. 2021 06 22; 77(24):3079-3133.
    View in: PubMed
    Score: 0.019
  12. A Return to Normal Is Not Good Enough. Circulation. 2021 05 04; 143(18):e893-e897.
    View in: PubMed
    Score: 0.019
  13. Nonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy Statement. Circulation. 2021 05 11; 143(19):e947-e958.
    View in: PubMed
    Score: 0.019
  14. COVID-19 at 1 Year: American Heart Association Presidents Reflect on the Pandemic. Circulation. 2021 03 02; 143(9):e746-e748.
    View in: PubMed
    Score: 0.019
  15. Taking a Stand Against Air Pollution-The Impact on Cardiovascular Disease: A Joint Opinion From the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology. Circulation. 2021 Apr 06; 143(14):e800-e804.
    View in: PubMed
    Score: 0.019
  16. Taking a Stand Against Air Pollution - The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology. Glob Heart. 2021 01 28; 16(1):8.
    View in: PubMed
    Score: 0.019
  17. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. J Am Coll Cardiol. 2020 07 14; 76(2):162-171.
    View in: PubMed
    Score: 0.018
  18. The Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020 04 14; 141(15):e743-e745.
    View in: PubMed
    Score: 0.018
  19. Advancing Healthcare Reform: The American Heart Association's 2020 Statement of Principles for Adequate, Accessible, and Affordable Health Care: A Presidential Advisory From the American Heart Association. Circulation. 2020 03 10; 141(10):e601-e614.
    View in: PubMed
    Score: 0.018
  20. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019 12; 50(12):3331-3332.
    View in: PubMed
    Score: 0.017
  21. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 11 05; 140(19):1578-1589.
    View in: PubMed
    Score: 0.017
  22. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 08; 12(8):e007604.
    View in: PubMed
    Score: 0.017
  23. Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. Circ Cardiovasc Interv. 2019 05; 12(5):e007086.
    View in: PubMed
    Score: 0.017
  24. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10?854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018 12 07; 39(46):4112-4121.
    View in: PubMed
    Score: 0.016
  25. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thromb Haemost. 2018 Dec; 118(12):2046-2052.
    View in: PubMed
    Score: 0.016
  26. Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheter Cardiovasc Interv. 2018 11 01; 92(5):E348-E355.
    View in: PubMed
    Score: 0.016
  27. Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. Am Heart J. 2018 07; 201:103-110.
    View in: PubMed
    Score: 0.016
  28. New Delivery Model for Rising-Risk Patients: The Forgotten Lot? Telemed J E Health. 2017 08; 23(8):649-653.
    View in: PubMed
    Score: 0.015
  29. The Academic Medical System: Reinvention to Survive the Revolution in Health Care. J Am Coll Cardiol. 2017 Mar 14; 69(10):1305-1312.
    View in: PubMed
    Score: 0.015
  30. Disaggregation of Cause-Specific Cardiovascular Disease Mortality Among Hispanic Subgroups. JAMA Cardiol. 2017 03 01; 2(3):240-247.
    View in: PubMed
    Score: 0.014
  31. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2017 02 01; 2(2):127-135.
    View in: PubMed
    Score: 0.014
  32. The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. J Am Coll Cardiol. 2016 10 25; 68(17):1898-1907.
    View in: PubMed
    Score: 0.014
  33. "Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. J Am Coll Cardiol. 2016 11 29; 68(21):2385-2387.
    View in: PubMed
    Score: 0.014
  34. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. Eur Heart J Acute Cardiovasc Care. 2018 Mar; 7(2):158-165.
    View in: PubMed
    Score: 0.014
  35. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016 06; 9(6).
    View in: PubMed
    Score: 0.014
  36. Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. Int J Cardiol. 2016 Jan 15; 203:708-13.
    View in: PubMed
    Score: 0.013
  37. Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015. J Am Heart Assoc. 2015 Nov 05; 4(11).
    View in: PubMed
    Score: 0.013
  38. High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. Am Heart J. 2016 Jan; 171(1):25-32.
    View in: PubMed
    Score: 0.013
  39. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):357-67.
    View in: PubMed
    Score: 0.013
  40. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. J Am Coll Cardiol. 2015 Feb 10; 65(5):465-76.
    View in: PubMed
    Score: 0.013
  41. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovasc Interv. 2014 Aug; 7(8):857-67.
    View in: PubMed
    Score: 0.012
  42. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014 Sep 01; 114(5):665-73.
    View in: PubMed
    Score: 0.012
  43. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Crit Pathw Cardiol. 2013 Jun; 12(2):65-105.
    View in: PubMed
    Score: 0.011
  44. Rescuing clinical trials in the United States and beyond: a call for action. Am Heart J. 2013 Jun; 165(6):837-47.
    View in: PubMed
    Score: 0.011
  45. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Circulation. 2013 Mar 05; 127(9):1052-89.
    View in: PubMed
    Score: 0.011
  46. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). J Am Coll Cardiol. 2013 Mar 05; 61(9):992-1025.
    View in: PubMed
    Score: 0.011
  47. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):336-46.
    View in: PubMed
    Score: 0.010
  48. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):347-56.
    View in: PubMed
    Score: 0.010
  49. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011 Aug 05; 109(4):428-36.
    View in: PubMed
    Score: 0.010
  50. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 02; 124(5):544-54.
    View in: PubMed
    Score: 0.010
  51. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31; 123(21):2434-506.
    View in: PubMed
    Score: 0.010
  52. Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting. Am J Cardiol. 2010 Dec 15; 106(12):1728-34.
    View in: PubMed
    Score: 0.009
  53. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv. 2009 Nov; 2(11):1083-91.
    View in: PubMed
    Score: 0.009
  54. Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009 Aug 13; 361(7):712-7.
    View in: PubMed
    Score: 0.009
  55. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg. 2007 Jun; 133(6):1604-11.
    View in: PubMed
    Score: 0.007
  56. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol. 2007 May 15; 99(10):1389-93.
    View in: PubMed
    Score: 0.007
  57. Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). Am J Cardiol. 2007 May 01; 99(9):1222-6.
    View in: PubMed
    Score: 0.007
  58. A comparison of acute coronary syndrome care at academic and nonacademic hospitals. Am J Med. 2007 Jan; 120(1):40-6.
    View in: PubMed
    Score: 0.007
  59. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. Health Aff (Millwood). 2007 Jan-Feb; 26(1):62-74.
    View in: PubMed
    Score: 0.007
  60. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006 Oct 09; 166(18):2027-34.
    View in: PubMed
    Score: 0.007
  61. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 01; 98(9):1172-6.
    View in: PubMed
    Score: 0.007
  62. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA. 2006 Apr 26; 295(16):1912-20.
    View in: PubMed
    Score: 0.007
  63. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2005 Sep 15; 96(6):750-5.
    View in: PubMed
    Score: 0.007
  64. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med. 2005 May; 12(5):431-8.
    View in: PubMed
    Score: 0.006
  65. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005 Mar; 149(3):474-81.
    View in: PubMed
    Score: 0.006
  66. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J. 2004 Nov; 148(5 Suppl):S34-9.
    View in: PubMed
    Score: 0.006
  67. Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Jun 16; 43(12):2153-9.
    View in: PubMed
    Score: 0.006
  68. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004 Mar 17; 43(6):972-8.
    View in: PubMed
    Score: 0.006
  69. Poverty, process of care, and outcome in acute coronary syndromes. J Am Coll Cardiol. 2003 Jun 04; 41(11):1948-54.
    View in: PubMed
    Score: 0.006
  70. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J. 2003 Jan; 145(1):73-9.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.